SG169325A1 - Promoters for expression in modified vaccinia virus ankara - Google Patents

Promoters for expression in modified vaccinia virus ankara

Info

Publication number
SG169325A1
SG169325A1 SG201100204-5A SG2011002045A SG169325A1 SG 169325 A1 SG169325 A1 SG 169325A1 SG 2011002045 A SG2011002045 A SG 2011002045A SG 169325 A1 SG169325 A1 SG 169325A1
Authority
SG
Singapore
Prior art keywords
expression
promoters
vaccinia virus
virus ankara
modified vaccinia
Prior art date
Application number
SG201100204-5A
Other languages
English (en)
Inventor
Sonja Leyrer
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of SG169325A1 publication Critical patent/SG169325A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/275Poxviridae, e.g. avipoxvirus
    • A61K39/285Vaccinia virus or variola virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG201100204-5A 2003-11-24 2004-10-27 Promoters for expression in modified vaccinia virus ankara SG169325A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200301730 2003-11-24
EP04000943A EP1536015B1 (de) 2003-11-24 2004-01-17 Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara

Publications (1)

Publication Number Publication Date
SG169325A1 true SG169325A1 (en) 2011-03-30

Family

ID=34442836

Family Applications (2)

Application Number Title Priority Date Filing Date
SG201100204-5A SG169325A1 (en) 2003-11-24 2004-10-27 Promoters for expression in modified vaccinia virus ankara
SG200802660-1A SG142300A1 (en) 2003-11-24 2004-10-27 Promoters for expression in modified vaccinia virus ankara

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG200802660-1A SG142300A1 (en) 2003-11-24 2004-10-27 Promoters for expression in modified vaccinia virus ankara

Country Status (18)

Country Link
US (3) US7816508B2 (de)
EP (4) EP1845164B1 (de)
JP (2) JP2007512009A (de)
KR (1) KR20060109873A (de)
CN (1) CN1898390A (de)
AT (4) ATE471383T1 (de)
AU (1) AU2004295382A1 (de)
BR (1) BRPI0416916A (de)
CA (1) CA2546680A1 (de)
DE (4) DE602004027767D1 (de)
DK (3) DK1845164T3 (de)
EA (1) EA012846B1 (de)
IL (4) IL174653A0 (de)
NO (1) NO20062948L (de)
NZ (1) NZ547405A (de)
SG (2) SG169325A1 (de)
UA (1) UA90098C2 (de)
WO (1) WO2005054484A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05680B1 (et) * 2000-11-23 2013-10-15 Bavarian Nordic A/S Muundatud vaktsiiniaviirus, selle valmistamine ja kasutamine, seda sisaldav farmatseutiline kompositsioon ning vaktsiin
DK1845164T3 (da) * 2003-11-24 2010-09-20 Bavarian Nordic As Promoterer til ekspression i modificeret vacciniavirus ankara
EP2042604A1 (de) * 2007-09-26 2009-04-01 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) VV-Promotergesteuerte Überexpression von rekombinanten Antigenen
WO2010060632A1 (en) * 2008-11-27 2010-06-03 Bavarian Nordic A/S Promoters for recombinant viral expression
US8394385B2 (en) * 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
US8613936B2 (en) 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
AU2011316164B2 (en) 2010-10-15 2016-01-14 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) influenza vaccine
EP2788021B1 (de) 2011-12-09 2017-01-18 Bavarian Nordic A/S Pockenvirus-vektor zur expression von bakteriellen antigen, welche mit tetanus toxin fragment c verbunden sind
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN106754921A (zh) * 2016-12-12 2017-05-31 孙浩 哺乳动物细胞表达启动子及其制造和使用方法
CN111107872A (zh) * 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EP1263936B1 (de) 2000-03-14 2005-09-21 Bavarian Nordic A/S Veränderter stamm des modifizierten vaccinia-virus ankara (mva)
EE05680B1 (et) * 2000-11-23 2013-10-15 Bavarian Nordic A/S Muundatud vaktsiiniaviirus, selle valmistamine ja kasutamine, seda sisaldav farmatseutiline kompositsioon ning vaktsiin
JP4554887B2 (ja) * 2001-03-08 2010-09-29 アメリカ合衆国 改変HIVエンベロープ、gag、およびpol遺伝子を発現するMVA
SI1404852T1 (sl) 2002-05-16 2006-04-30 Bavarian Nordic As Ekspresija genov v modularnem vakcinija virusa Ankara z uporabo ATI promotorja kravjih ospic
AU2003255315A1 (en) * 2002-08-07 2004-02-25 Bavarian Nordic A/S Vaccinia virus host range genes to increase the titer of avipoxviruses
DK1845164T3 (da) * 2003-11-24 2010-09-20 Bavarian Nordic As Promoterer til ekspression i modificeret vacciniavirus ankara

Also Published As

Publication number Publication date
DK1845164T3 (da) 2010-09-20
IL199127A (en) 2010-12-30
CA2546680A1 (en) 2005-06-16
EP1845164B1 (de) 2010-06-16
DK1689872T3 (da) 2009-04-27
EA012846B1 (ru) 2009-12-30
KR20060109873A (ko) 2006-10-23
ATE504654T1 (de) 2011-04-15
DE602004009743D1 (de) 2007-12-13
EP1956094A1 (de) 2008-08-13
US20080112971A1 (en) 2008-05-15
EP1845164A3 (de) 2008-03-19
JP2011067219A (ja) 2011-04-07
DE602004027767D1 (de) 2010-07-29
US7816508B2 (en) 2010-10-19
NZ547405A (en) 2008-06-30
NO20062948L (no) 2006-08-23
ATE420191T1 (de) 2009-01-15
IL199128A (en) 2011-03-31
CN1898390A (zh) 2007-01-17
SG142300A1 (en) 2008-05-28
DE602004009743T2 (de) 2008-08-28
EP1845164A2 (de) 2007-10-17
DE602004032187D1 (de) 2011-05-19
IL199126A (en) 2010-12-30
ATE377088T1 (de) 2007-11-15
EP1536015B1 (de) 2007-10-31
ATE471383T1 (de) 2010-07-15
US20110014242A1 (en) 2011-01-20
AU2004295382A1 (en) 2005-06-16
EP1536015A1 (de) 2005-06-01
JP2007512009A (ja) 2007-05-17
DK1536015T3 (da) 2008-02-18
EP1689872B1 (de) 2009-01-07
EA200601043A1 (ru) 2006-10-27
US20110008792A1 (en) 2011-01-13
BRPI0416916A (pt) 2007-01-23
DE602004018975D1 (de) 2009-02-26
IL174653A0 (en) 2006-08-20
UA90098C2 (en) 2010-04-12
EP1956094B1 (de) 2011-04-06
WO2005054484A1 (en) 2005-06-16
EP1689872A1 (de) 2006-08-16

Similar Documents

Publication Publication Date Title
IL199127A (en) Promoters for expression in modified vaccinia virus ankara (mva) and vectors comprising said promoters
HK1076835A1 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
WO2005052143A3 (de) Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
WO2004087874A3 (en) Novel nucleic acids and polypeptides
WO2007016715A3 (en) Immune response inducing preparations
ATE532861T1 (de) Expressionsvektor
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
EP0953641A3 (de) Für Neospora Proteine kodierende polynukleotid Moleküle
WO2002086059A3 (en) Recombinant vaccinia viral vectors
EP1816203A4 (de) Für coronavirus-ähnliche partikel codierender expressionsvektor
WO2005094415A3 (en) Recombinant vectors and methods for inducing an immune response
WO2008134720A3 (en) Inert dna sequences for efficient viral packaging and methods of use
WO2005010035A3 (en) Alternate reading frame polypeptides derived from hepatitis c and methods of their use
WO2005001096A8 (fr) Vaccins contre le sras
EP1221487A3 (de) Für Neosporaproteine kodierende Nukleinsäuren
WO2003091393A3 (en) Nucleic “acid molecules encoding human proteins, and uses thereof”